Entrada Therapeutics, Inc.

Name: Entrada Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

TRDANasdaqCIK 1689375HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$898.0k, Q2 FY2026

Operating income−$45.0m, Q2 FY2026

Net income−$42.8m, Q2 FY2026

Entrada Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	43.7	41.8	59.1	94.7	19.6	37.4	20.6	2.0	1.6	1.3	0.9	0.9
Research and development	$m	22.2	28.3	28.6	32.0	31.3	33.4	32.1	37.9	38.4	34.0	33.1	35.4
Operating income	$m	14.0	4.9	21.1	53.4	(21.7)	(5.9)	(21.8)	(46.8)	(47.1)	(42.2)	(42.3)	(45.0)
Income tax	$m	(17.4)	18.7	1.8	2.8	(1.9)	(1.9)	0.0	0.2	0.7	0.1	0.0	0.0
Net income	$m	35.5	(9.5)	23.5	55.0	(14.0)	1.1	(17.3)	(43.1)	(44.1)	(39.2)	(39.7)	(42.8)
Diluted EPS	$ per share	1.02	not reported	0.68	1.55	(0.35)	not reported	(0.42)	(1.04)	(1.06)	not reported	(0.95)	(1.01)
Basic EPS	$ per share	1.07	not reported	0.70	1.61	(0.35)	not reported	(0.42)	(1.04)	(1.06)	not reported	(0.95)	(1.01)

Balance sheet

Cash and equivalents$99.3m, Q2 FY2026

Shareholders' equity$233.4m, Q2 FY2026

Entrada Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	51.9	67.6	68.4	185	78.0	101	67.8	72.5	93.3	90.4	76.4	99.3
Current assets	$m	383	370	414	490	465	440	403	369	338	306	267	233
Total assets	$m	485	469	511	582	555	526	486	449	413	377	336	299
Current liabilities	$m	165	159	174	85.8	70.6	39.5	18.4	19.8	24.0	24.5	19.2	21.4
Total liabilities	$m	238	227	241	152	132	97.6	69.2	69.3	72.2	71.2	64.7	65.5
Shareholders' equity	$m	247	242	269	430	422	429	417	380	341	306	271	233

Cash flow

Operating cash flow−$32.5m, Q2 FY2026

Capital expenditure$11.0k, Q2 FY2026

Entrada Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(24.5)	(4.0)	(25.5)	39.8	(24.3)	(31.6)	(38.5)	(29.5)	(28.3)	(32.2)	(41.7)	(32.5)
Capital expenditure	$m	1.4	1.0	0.8	1.0	0.6	0.6	1.1	0.3	(0.2)	(0.2)	0.0	0.0

Diluted shares (weighted)42.22m, Q2 FY2026

Entrada Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	31.3	32.4	33.2	34.8	34.8	35.5	40.6	41.1	41.3	41.5	41.8	42.2

Shares outstanding: 38.94m at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.